Historical Valuation
Myriad Genetics Inc (MYGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.67 is considered Undervalued compared with the five-year average of -7.07. The fair price of Myriad Genetics Inc (MYGN) is between 16.72 to 31.31 according to relative valuation methord. Compared to the current price of 6.57 USD , Myriad Genetics Inc is Undervalued By 60.7%.
Relative Value
Fair Zone
16.72-31.31
Current Price：6.57
60.7%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Myriad Genetics Inc (MYGN) has a current Price-to-Book (P/B) ratio of 1.53. Compared to its 3-year average P/B ratio of 2.04 , the current P/B ratio is approximately -25.01% higher. Relative to its 5-year average P/B ratio of 2.11, the current P/B ratio is about -27.28% higher. Myriad Genetics Inc (MYGN) has a Forward Free Cash Flow (FCF) yield of approximately -2.92%. Compared to its 3-year average FCF yield of -6.82%, the current FCF yield is approximately -57.20% lower. Relative to its 5-year average FCF yield of -5.55% , the current FCF yield is about -47.47% lower.
P/B
Median3y
2.04
Median5y
2.11
FCF Yield
Median3y
-6.82
Median5y
-5.55
Competitors Valuation Multiple
AI Analysis for MYGN
The average P/S ratio for MYGN competitors is 2.81, providing a benchmark for relative valuation. Myriad Genetics Inc Corp (MYGN.O) exhibits a P/S ratio of 0.67, which is -76.15% above the industry average. Given its robust revenue growth of -3.56%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for MYGN
1Y
3Y
5Y
Market capitalization of MYGN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MYGN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MYGN currently overvalued or undervalued?
Myriad Genetics Inc (MYGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.67 is considered Undervalued compared with the five-year average of -7.07. The fair price of Myriad Genetics Inc (MYGN) is between 16.72 to 31.31 according to relative valuation methord. Compared to the current price of 6.57 USD , Myriad Genetics Inc is Undervalued By 60.70% .
What is Myriad Genetics Inc (MYGN) fair value?
MYGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Myriad Genetics Inc (MYGN) is between 16.72 to 31.31 according to relative valuation methord.
How does MYGN's valuation metrics compare to the industry average?
The average P/S ratio for MYGN's competitors is 2.81, providing a benchmark for relative valuation. Myriad Genetics Inc Corp (MYGN) exhibits a P/S ratio of 0.67, which is -76.15% above the industry average. Given its robust revenue growth of -3.56%, this premium appears unsustainable.
What is the current P/B ratio for Myriad Genetics Inc (MYGN) as of Jan 13 2026?
As of Jan 13 2026, Myriad Genetics Inc (MYGN) has a P/B ratio of 1.53. This indicates that the market values MYGN at 1.53 times its book value.
What is the current FCF Yield for Myriad Genetics Inc (MYGN) as of Jan 13 2026?
As of Jan 13 2026, Myriad Genetics Inc (MYGN) has a FCF Yield of -2.92%. This means that for every dollar of Myriad Genetics Inc’s market capitalization, the company generates -2.92 cents in free cash flow.
What is the current Forward P/E ratio for Myriad Genetics Inc (MYGN) as of Jan 13 2026?
As of Jan 13 2026, Myriad Genetics Inc (MYGN) has a Forward P/E ratio of 196.17. This means the market is willing to pay $196.17 for every dollar of Myriad Genetics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Myriad Genetics Inc (MYGN) as of Jan 13 2026?
As of Jan 13 2026, Myriad Genetics Inc (MYGN) has a Forward P/S ratio of 0.67. This means the market is valuing MYGN at $0.67 for every dollar of expected revenue over the next 12 months.